© 2021 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
Blood Cancer
Updates on Pediatric Leukemia Research
June 07, 2021
Researchers are making progress in identifying drugs that target certain mutations.
Positive Results for Vyxeos in Combination With Other Drugs Reported at ASCO Meeting
June 06, 2021
Phase 1b results show manageable toxicities with Venclexta and Rydapt.
3 Updates About Chronic Lymphocytic Leukemia
June 02, 2021
NCCN recommends Brukinsa for CLL/SLL even though it is FDA-approved for mantel cell lymphoma.
Joe Biden Wants to Cure Cancer. Here’s Where to Start
January 20, 2021
Deposing the ‘Emperor of All Maladies’ will take a diverse toolkit, not a single moonshot.
Bringing CAR-T Cell Therapy to the Community
November 23, 2020
In the early going, patients seeking the expensive, customized cancer treatments called CAR-T cell therapy had to go to an academic medical center. But that’s changing, as Duncan Allen, M.H.A., of the community cancer network OneOncology explains.
FDA Updates: Blood Cancers, Orphan Drug Designations Get Priority
August 02, 2020
In a busy week, FDA approved ground-breaking therapies in hematologic cancers and issued Orphan Drug designations in areas of significant unmet need.
5 Developments Changing the CAR-T Landscape
June 28, 2020
An off-the-shelf version of CAR-T therapy that uses the immune system’s natural killer cells is a possibility. But the high price of CAR-T shows some doubts about how widely it can be used.
Cancer Treatment Developments
November 10, 2019
Cancer care enters a new, exciting phase, experts say.
The Cost Burden of Blood Cancer Treatments
October 29, 2019
New study shows that although costly, more effective treatments increase survival rates in Medicare patients.
Four Things to Know About Providing CAR T-Cell Treatment
July 14, 2019
Top oncology experts share how they deliver these therapies to patients in need.